Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched By Boehringer Ingelheim Corporation And Eli Lilly and Company In Partnership With The International Diabetes Federation

Published: Dec 02, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company today announced the launch of the largest multinational survey to investigate early conversations between physicians and people living with Type 2 Diabetes (T2D). The survey was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians across 26 countries worldwide. The findings will provide in-depth insights into early conversations at diagnosis and when an additional therapy may be required beyond the first medication. The survey will also investigate how these early conversations may be linked to an individual’s wellbeing and other self-reported outcomes.

Help employers find you! Check out all the jobs and post your resume.

Back to news